Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06558188

Combined Anabolic Therapy

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Osteoporosis, Postmenopausal Bone Diseases Bone Diseases, Metabolic Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases Osteoporosis

Age range

45 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location status: Recruiting

Location contact

Aparna Patnaik, BA

CONTACT

[email protected]

617-726-6129

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • women aged 45+
  • postmenopausal
  • osteoporotic with high risk of fracture

Exclusion criteria

  • no significant previous use of bone health modifying treatments
  • known congenital or acquired bone disease other than osteoporosis
  • significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
  • abnormal calcium or parathyroid hormone level
  • serum vitamin D <20 ng/dL
  • anemia (hematocrit <32%)
  • history of malignancy (except non-melanoma skin carcinoma)
  • excessive alcohol use or substance abuse
  • known contraindications to romosozumab or teriparatide

Treatment and study plan

Romosozumab

Drug

romosozumab 210 milligrams monthly

Other names: Evenity

Teriparatide

Drug

teriparatide 20 micrograms daily

Other names: Forteo

Primary outcomes

  1. Lumbar spine areal bone mineral density

    Time frame: Month 0 to 12

    Change in lumbar spine bone density between month 0 and month 12

Study contacts

Contact information is provided by the study sponsor or research team.

Aparna Patnaik, BA

CONTACT

[email protected]

617-726-6129

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Registry information

Official study title

Combined Anabolic Therapy Study

Acronym: CAT

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Aug 16, 2024
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.